Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2019

01-12-2019 | Endocrine imaging

Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by 18F-FDOPA PET/CT in a MEN-2A asymptomatic patient

Authors: Marianela Rotania, Gérard Chabrier, Alessio Imperiale

Published in: Endocrine | Issue 3/2019

Login to get access

Excerpt

Type-2A multiple endocrine neoplasia (MEN-2A) syndrome is a rare autosomal dominant inheritance disease characterized by the presence of pheochromocytoma (PHEO), medullary thyroid carcinoma (MTC), and parathyroid adenoma or hyperplasia. In patients with MEN-2A, PHEO is frequently asymptomatic and bilateral, and MTC is multifocal, usually representing the first manifestation of the disease. …
Literature
1.
D. Taïeb, R.J. Hicks, E. Hindié, B.A. Guillet, A. Avram, P. Ghedini et al. European association of nuclear medicine practice guideline/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur. J. Nucl. Med. Mol. Imaging 46, 2112–2137 (2019)CrossRef
2.
S. Rasul, S. Hartenbach, K. Rebhan, A. Göllner, G. Karanikas, M. Mayerhoefer et al. [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery. Eur. J. Nucl. Med. Mol. Imaging 12, 2159–2169 (2018)CrossRef
3.
L. Brammen, M.B. Niederle, P. Riss, C. Scheuba, A. Selberherr, G. Karanikas et al. Medullary thyroid carcinoma: do ultrasonography and F-DOPA-PET-CT influence the initial surgical strategy? Ann. Surg. Oncol. 25, 3919–3927 (2018)CrossRef
Metadata
Title
Synchronous bilateral pheochromocytomas and bilobar medullary thyroid carcinoma revealed by 18F-FDOPA PET/CT in a MEN-2A asymptomatic patient
Authors
Marianela Rotania
Gérard Chabrier
Alessio Imperiale
Publication date
01-12-2019
Publisher
Springer US
Published in
Endocrine / Issue 3/2019
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-019-02074-w

Other articles of this Issue 3/2019

Endocrine 3/2019 Go to the issue

Original Article

Risk factors for vertebral fracture in primary hyperparathyroidism

Endocrine Imaging

Unusual uptake of 131iodine in bilateral ovarian endometriosis cysts in a patient with thyroid cancer

Original Article

Synchronous bilateral adrenalectomy in ACTH-dependent hypercortisolism: predictors, biomarkers and outcomes

Mini Review

Network medicine and type 2 diabetes mellitus: insights into disease mechanism and guide to precision medicine

Research Letter

Body mass index predicts resistance to active vitamin D in patients with hypoparathyroidism

Original Article

The tendency of reduced periodontal destruction in acromegalic patients showing similar inflammatory status with periodontitis patients
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits